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The USPSTF has issued recommendation against the screening of prostate cancer
using PSA levels for men younger than 75 years of age, noting insufficient
evidence that benefits outweigh the harm associated with the screening test.
Since then, practices and clinics have reported reduced screening measures with
an associated increase in prostate cancer diagnoses following the
recommendation [7].
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According to the National Cancer Institute, prostate cancer is the most common
non-cutaneous malignancy diagnosed in American men. Approximately 164,690
men will be diagnosed and 29,430 men will die from prostate cancer (PCa) in
2018 [1]. Prostate cancer specific antigen (PSA) is a serine-protease enzyme
secreted by both normal and neoplastic prostatic tissue [2]. PSA is secreted into
the glandular ducts of the prostate, and is elevated in the serum with prostatic
inflammatory and neoplastic disease, thus serving as a marker for prostatic
metastasis [2].
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Figure 2. Average age for patient groups admitted
before and after 2012, p<0.05 (N= 619 vs 687,
respectively).

Post-2012

Figure 3. Average PSA levels in patients
admitted before and after 2012, p>0.05 NS
(N= 619 vs 687, respectively).
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Since the introduction of prostate specific antigen (PSA) the diagnosis incidence
of prostate cancer has increased drastically. Over the same time period, prostate
cancer mortality has decreased almost 40% [1,3,4]. The United States Preventive
Services Task Force (USPSTF), however, recommended against prostate cancer
screening in men older than age 75 and noted insufficient evidence to determine
the balance of benefits and harms of screening for prostate cancer in men
younger than age 75, grade D (Fig. 1) [5]. As a result of the USPSTF
recommendations, there has been a decrease in prostate cancer screening using
prostate needle biopsies, digital rectal exams and PSA levels [6,7].
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Figure 6. Age-stratification shows an
55 - 69 increase in the majority of admitted patients
from being ≥70 years of age (51%) to being
55-69 years (55%) after the year 2012 (Chi>= 70 squared test p < .01).
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We investigated the impact of the USPSTF recommendation on the new
diagnoses of PCa in a community based private clinical practice. We report a
shift in the PCa characteristics of admitted patients with elevated serum PSA
levels. Overall, patients admitted were younger after the recommendations.
Specifically more patients below the age of 70 years were admitted due to
elevated PSA levels after 2012, and less were admitted over the age of 70. In
addition, patients presented with a significantly more developed prostatic tumour
(GG ≥ 2), and more patients were seen with intermediate and high risk cancer
upon examination as compared to low and very risk cancer.
These observations suggest a possible role for the recommendations in the
increasing trend of more advanced prostatic neoplasia seen on initial
examination. This could be due to the decrease of early screening measures with
less biopsies, digital rectal exams as well as PSA level monitoring performed by
primary care physicians. However, this merits further investigation into the role
of the recommendations in higher risk prostate cancer diagnoses.
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Figure 1. The USPSTF recommendation grade definitions [8].
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Figure 4. Patients sub-grouped into gleason
score (GG) shows an increase in clinically
significant prostate cancer GG ≥ 2 in the
post-2012 group compared to pre-2012,
with 430 patients vs 351, respectively (Chisqaured test p < .05).

We observed that following the 2012 USPSTF recommendations, there was a
significant increase in patients with clinically significant prostate cancer GG ≥ 2,
with the majority being 55-65 years of age. In addition we observed a decrease
in the diagnosis of very low and low risk PCa with an increased incidence of
intermediate and high risk PCa.
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The purpose of our study is to assess the effects of the USPSTF grade D
recommendation for PSA based screening on new PCa diagnoses within a largecommunity based private practice setting.
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Figure 5. A significant relationship is
depicted between cancer risk and time period
when patients are admitted. There is an
increase in patients with intermediate and
very high risk cancer in the post-2012 group,
and less in the very low and low risk group
compared to the pre-2012 group (Chi-squared
test p < 0.01).
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